For the last several years The New York Times has run articles almost every week exposing abuses by the prescription drug industry. The stories usually document indirect payoffs to doctors for prescribing drugs, such as exorbitant speaker fees, expense-paid trips to industry-sponsored seminars at resort locations, or excessive fees for participating in clinical trials. In some cases the articles document outright kickbacks, as when the NYT reported that doctors who administer an anemia drug in their office could receive tens of thousands of dollars annually in rebates from the manufacturer.
The abuses also affect the research that is used to establish a drug’s safety and effectiveness. There have been many incidents in which drug companies have concealed evidence that their drugs may not be more effective than cheaper alternatives. In some cases, they have concealed evidence of negative side effects from the public and the Food and Drug Administration. And, there is the problem that drug companies often pay researchers to sign their names to articles touting the benefits of their drugs, which the researchers did not write.
Such abuses should not be surprising to anyone who appreciates the value of a competitive market. The root cause of all of these problems is government-granted patent monopolies that allow the pharmaceutical industry to sell drugs at prices that can exceed the cost of production by a factor of a hundred, or more. Last fall, Wal-Mart began selling hundreds of generic drugs for $4 per prescription. The vast majority of brand drugs could also be profitably sold for $4 per prescription, if it were not for the patent monopoly granted by the government.
As a result of patent monopolies, drug companies can sell drugs for hundreds of dollars that cost them a few dollars to manufacture. This situation invites the sort of corruption that NYT documents regularly in its pages.
Drug patents do serve a purpose: they provide an incentive to the industry to develop new drugs. However, there are other ways in which this research can be financed. The federal government already spends nearly $30 billion a year on biomedical research conducted through the National Institutes of Health. By doubling this amount, it could probably replace the research conducted by the pharmaceutical industry, most of which currently goes to develop copycat drugs (another problem of the patent system).
As another possible alternative, Nobel Laureate Joe Stiglitz has suggested a prize system, in which the government would buy out patents at prices determined by their usefulness. The patents would then be placed in the public domain so that all new drugs could be sold as generics.
The United States spends almost $240 billion a year on prescription drugs, which comes to $800 per person. The cost of prescription drugs are a major burden to millions of low and moderate income households as well as to the government itself, which now picks up much of the tab through Medicare and Medicaid. In addition, hundreds of millions of people in the developing world are denied access to prescription drugs because they cannot afford to pay patent-protected drug prices.
The time has long passed when we should be seriously considering alternatives to patent financed research for prescription drugs. However, the power of the pharmaceutical industry has largely kept any such discussion off the political agenda.
A recent article in The Nation triggered a debate in the blogosphere as to whether the methodology of mainstream economics prevents it from considering important issues. In the case of patent financing of prescription drug research, there are no methodological issues at stake. Economists could use the exact same models that show the losses from trade barriers on shoes and shirts to quantify the much larger economic harm from patent monopolies on prescription drugs.
Unfortunately, the political force behind protection for prescription drugs is much greater than the political force behind protection for shoes and shirts. Therefore, we can look forward to reading many more articles in the NYT about abuses in the prescription drug industry.
By Dean Baker
t r u t h o u t | Columnist